Thesis: Recent competitive pressures and potential regulatory delays have shifted investor sentiment towards caution, impacting growth expectations.
★ Analysts see FY2026 revenue reaching $5.6B — +9.8% growth in a single year.
What Moves the Stock 1 Regulatory approvals for new devices and software enhancements 2 Growth in sleep apnea diagnosis rates and COPD prevalence 3 Expansion into emerging markets, particularly in Asia-Pacific 4 Changes in reimbursement policies affecting device affordability 5 Sleep apnea devices (approximately 60% of total revenue) 6 Chronic obstructive pulmonary disease (COPD) devices (approximately 25% of total revenue) 7 Software and cloud services (approximately 15% of total revenue) 8 Telehealth expansion in respiratory care 176 202 228 254 280 210.20 0KW4.L Daily 210.20 Mar '26 Apr '26 Jun '26 Jul '26
My Notes "Management noted, 'While we continue to innovate, the competitive landscape is evolving rapidly, which may affect our market position.'" Moat: ResMed's competitive advantage is supported by its strong brand and proprietary technology… growth - Investors are likely attracted to ResMed due to its strong revenue growth and innovative product pipeline. Low - ResMed's business is not heavily reliant on debt financing, and interest rate changes have minimal impact on its operations. Watch on earnings: Sleep apnea diagnosis rates, Market share in the sleep and respiratory device segments, Growth in software subscription revenue. One Sentence Summary: ResMed: the story is balanced — regulatory approvals for new devices and software enhancements.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.